Document is current

Any future updates will be listed below

Cost-utility of IDegLira versus alternative basal insulin intensification therapies in patients with type 2 diabetes mellitus uncontrolled on basal insulin in a Chinese setting

Crossref DOI link: https://doi.org/10.1186/s13098-025-01722-8

Published Online: 2025-05-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark